Ribo's proprietary technologies including unique delivery technologies for delivering oligonucleotide therapeutics for various targets and indications, as well as chemical modification technologies, novel , impurity analytical technologies, bioanalytical technologies, as well as manufacture technologies are comprehensively protected by patent, patent applications in major global pharmaceutical markets including China, the United States, Europe, Japan, South Korea and other countries/regions as well as trade secrets. Additionally, more and more collaborations with other companies in the research, development, transfer, license-out or license-in of patented technologies of pharmaceuticals and small nucleic acids are established and expected to advance the development of small nucleic acid pharmaceuticals. Ribo's IP portfolios and the collaborations with other companies provide solid support for the product pipelines of the company and enable us to possibly contribute to the health of mankind by meeting the unmet medical needs.
Recently two important platform technologies independently developed by Ribo have been granted patents in major jurisdictions, which relate to two key platform technologies for siRNA pharmaceuticals: RIBO-GalSTARTMdelivery technology and RSC2.0 siRNA chemical modification technology. Up to now, RIBO-GalSTARTM delivery platform technology has been granted patents or received Notice of Grant in China, United States, Korea, India, Russia, Australia, South Africa, HongKong, Macau and Taiwan. RSC2.0 siRNA chemical modification technology has been granted patents or received Notice of Grant in United States, Australia, Canada and Taiwan. It is expected that these two platform technologies will be granted patents subsequently in other jurisdictions.
Regarding siRNA delivery and chemical modification technologies, in the review article titled "Delivery of therapeutic small interfering RNA: The Current Patent-Based landscape" (Molecular Therapy: Nucleic Acids Vol. 29 Sep. 2022), Yu Chen et al. from University of Macau summarized 11,509 publicly available siRNA delivery technology patents worldwide from 2000 to 2020. According to the review article, the Chinese Academy of Sciences and Ribo are the only two Chinese entities in the TOP 20 list. Excluding universities and research institutions, Ribo ranks 6th among all biotechnology and pharmaceutical companies globally in the siRNA delivery patent list as shown in the table below.
As of September 25th, 2024, RIBO has been the patentee of 120 patent families worldwide, totaling 378 applications and patents among which 180 patents have received Notice of Grant or been granted. These two important technologies being grant patents recently fully reflects RIBO's research and development innovation capabilities and comprehensive intellectual property protection system. Ribo will continue to carry out its patent layout strategy and protect key technologies globally.
(Image from: Delivery of therapeutic small interfering RNA: The Current Patent-Based landscape. Molecular Therapy: Nucleic Acids Vol.29 Sep.2022)
| 少妇无码又大又粗又深免小说 | 丰满人妻熟妇乱偷人无码蜜桃 | 中文字幕无码人妻少妇免费视频 | 农村妇女一区二区三区 | 少妇做爰毛片A片成人影院 特级大胆西西4444人体 | 无码人妻精品一区 | 亚洲熟妇自拍偷拍另欧美一百度一百度 | 色情网站在线播放免费 | 国产一区二区三区在线 | www.免费观看在线.学习资料黄色 | 国产精品操操黑料影院 | 少妇无码无套AV一区 | 国产又爽又粗又猛又色又 | 亚洲一区二区三区四区av电影 | 国产成人精品免费视频 | 国产日本美国在线视频观看视频 | 日韩 成人 无码 视频 | 亚洲免费高清视频 | 免费婬秽片人人爽人人躁 | 成人做爰黄A片免费看直播室 | 最新中文字幕在线 | 国模精品无码一区二区免费蜜桃 | 国产伦精品一级A片视频夜夜 | 91久久国产综合久久91精品网站 | 欧美黄片免费在线观看 | 精品码产区一区二视频 | 又大又粗又长又爽的视频 | 一级黄色超级超级片中国 | 最好看的中文在线观看 | 少妇一级婬片免费看 | 久产久久精网页版白丝 | 中文人妻熟女乱又乱精品 | 美女会所吞精口爆 | 搡老熟女大熟了88AV一区二区 | 农村人甜伦一区二区三区 | 国产成人午夜精品无码区久久麻豆 | jiqingxiaoshuo综合婷婷 | 国产色情aⅴ一级毛片黄 | 精品一二三四区在线电影 | 66-m摸成人久久久 |